Chronic neuroblastoma (Q44128430)

30 November 2017

Chronic neuroblastoma (English)

1 reference

30 November 2017

Brian H Kushner

1

1 reference

30 November 2017

Kim Kramer

series ordinal

2

1 reference

30 November 2017

Nai-Kong V Cheung

series ordinal

3

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

30 November 2017

1 reference

30 November 2017

95

1 reference

30 November 2017

6

1 reference

30 November 2017

1366-1375

1 reference

Biology and treatment of neuroblastoma

30 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Neuroblastoma in adults and adolescents: an indolent course with poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Late recurrence of neuroblastoma: a report of five cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Long-term survival in refractory recurrent neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group "Survey".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Oral etoposide for refractory and relapsed neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Dose-intensive use of cyclophosphamide in ablation of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Neuroblastoma, its natural history and prognosis: a study of 487 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic charcter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St Jude Children's Research Hospital experience, 1962 to 1988

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Monoclonal antibody-based therapy of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Osseous metastases in neuroblastoma. A 17-year survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Recrudescence of neuroblastoma after apparent cure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Stage IV-N: a favorable subset of children with metastatic neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10800

7 January 2021

Identifiers

DOI

10.1002/CNCR.10800

1 reference

30 November 2017

1 reference